日本多中心队列中PRESERFLO微型分流管植入术的结局与失败危险因素
这项日本多中心回顾性队列研究纳入699例(856眼)接受PRESERFLO微型分流管(PMS)植入且随访≥3个月的患者,评估真实世界结局及手术失败危险因素。术后12个月中位眼压从术前18 mmHg降至11 mmHg,中位用药从4种降至0种(P < .001)。标准A、B、C下完全成功率分别为69.5%、67.6%、59.4%,条件成功率分别为81.0%、77.3%、66.0%。
要点
- 术后12个月中位眼压从18 mmHg降至11 mmHg,中位用药从4种降至0种(P < .001)。
- 标准A、B、C下完全成功率分别为69.5%、67.6%、59.4%,条件成功率分别为81.0%、77.3%、66.0%。
- 用药更多及既往或同期白内障手术是完全成功失败的危险因素,高龄和后管固定为保护因素。
核心结论
- PMS植入在日本大型队列中实现持续眼压降低、减少用药且安全性良好,强调患者选择与手术技术对优化结局的重要性。
研究设计与样本
- 多中心、回顾性队列研究,纳入699例(856眼)接受PMS植入且术后随访≥3个月的患者。
- 主要结局指标为术后12个月完全与条件手术成功率及失败危险因素。
- 手术成功定义为标准A、B、C,分别对应眼压阈值≤18、≤15、≤12 mmHg,且均需较基线降低≥20%。
- 结局分为完全成功(CS,不用药)或条件成功(QS,用药或不用药)。
- 采用Kaplan-Meier和Cox回归分析评估成功率及危险因素。
主要发现
- 中位眼压从术前18 mmHg降至术后12个月11 mmHg,中位用药从4种降至0种(P < .001)。
- 术后12个月,标准A、B、C下CS率分别为69.5%、67.6%、59.4%,对应QS率分别为81.0%、77.3%、66.0%。
- 所有三项标准下CS失败的危险因素包括用药更多及既往或同期白内障手术,高龄和后管固定为保护因素。
关键数值与推荐
- 手术成功标准A、B、C分别对应眼压阈值≤18、≤15、≤12 mmHg,且均需较基线降低≥20%。
- 完全成功(CS)定义为不用药达到上述标准,条件成功(QS)定义为用药或不用药达到上述标准。
- 术后12个月CS率:标准A 69.5%、标准B 67.6%、标准C 59.4%;QS率:标准A 81.0%、标准B 77.3%、标准C 66.0%。
临床怎么用
- PMS植入可考虑用于需要降低眼压并减少用药的患者,但应重视患者选择与手术技术以优化结局。
- 用药负担较重及既往或同期白内障手术者完全成功失败风险较高,高龄和后管固定可能有利于结局。
局限性
- 本研究为回顾性队列研究,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate real-world outcomes of PRESERFLO MicroShunt (PMS) implantation and identify risk factors for surgical failure in a large multicenter Japanese cohort. DESIGN: Multicenter, retrospective cohort study. METHODS: This study involved 699 patients (N = 856 eyes) who underwent PMS implantation with ≥ 3 months of follow-up postsurgery. The main outcome measures were 12-month-postoperative complete and qualified surgical success and risk factors for failure. Surgical success was defined by three criteria: A, B, and C corresponded to the intraocular pressure (IOP) thresholds of ≤ 18, ≤15, and ≤ 12 mm Hg, respectively, each combined with a ≥ 20% reduction from baseline. Outcomes were categorized as complete success (CS, without medication) or qualified success (QS, with or without medication). Kaplan-Meier and Cox regression analyses were used to evaluate success rates and risk factors. RESULTS: Median IOP decreased from 18 mm Hg preoperatively to 11 mm Hg at 12 months postoperatively, with median medications reduced from 4 to 0 (P < .001). At 12-months postoperative, CS rates were 69.5%, 67.6%, and 59.4% under Criteria A, B, and C, respectively; corresponding QS rates were 81.0%, 77.3%, and 66.0%, respectively. Risk factors for CS failure across all three criteria included greater medication use and prior or concomitant cataract surgery, whereas older age and posterior tube fixation were protective. CONCLUSIONS: PMS implantation achieved sustained IOP reduction, decreased medication use, and favorable safety in a large Japanese cohort, underscoring the importance of patient selection and surgical technique in optimizing outcomes.
引用
- Mieno H, Mori K, Kano K, et al. Outcomes and Risk Factors for Failure After PRESERFLO™ MicroShunt Implantation in a Multicenter Japanese Cohort. Am J Ophthalmol. 2026. PMID: 41850668. doi:10.1016/j.ajo.2026.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。